Advanced Search
Disease Phase
Title Drug
Clinical Trials Listing
  • < Previous
  • 1
  • Next >
  • Penn Treatment Trials (8)
  • Penn Non-Treatment Trials (8)
  • Phase 1: Solid Tumor Trials (0)
  • Proton Therapy Trials (0)
Active treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
UPCC 16412 A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physician's Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis III Chemotherapy, Hormonal Therapy, Immunotherapy, Signal Transduction Inhibitor melphalan; thalidomide; cyclophosphamide; dexamethasone; lenalidomide; MLN9708
690 A Trial of Single Autologous Transplant With or Without Consolidation Therapy Versus Tandem Autologous Transplant With Lenalidomide Maintenance for Patients With Multiple Myeloma (BMT CTN 0702) III Bone Marrow Transplant / Stem Cell Transplant, Hormonal Therapy, Immunotherapy, Signal Transduction Inhibitor bortezomib; dexamethasone; lenalidomide
UPCC 07409 Randomized Phase II Trial of CD3/CD28 Activated Id-KLH Primed Autologous Lymphocytes in Patients With Myeloma Undergoing Autologous Transplant II Immunotherapy Id-KLH
CR100755 A Phase 2, Randomized, Blinded, Placebo-controlled, Multicenter Study of Siltuximab (Anti IL 6 Monoclonal Antibody) in Subjects With High-risk Smoldering Multiple Myeloma II Immunotherapy siltuximab
UPCC 27412 A Phase I/II Study of the Tolerability of Lenalidomide and Low Dose Dexamethasone in Previously Treated Multiple Myeloma Patients With Impaired Renal Function I / II Hormonal Therapy, Immunotherapy dexamethasone; lenalidomide
AMyC 10-MM-01 A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma I / II Hormonal Therapy, Immunotherapy, Signal Transduction Inhibitor dexamethasone; carfilzomib; pomalidomide
ACY-100 A Phase 1/2, Open-Label, Multicenter Study of ACY-1215 Administered Orally as Monotherapy and in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma I / II Hormonal Therapy, Signal Transduction Inhibitor bortezomib; dexamethasone; Rocilinostat
UPCC 24412 A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Immunoregulatory Activity, and Preliminary Antitumor Activity of Anti-Programmed-Death 1 (PD-1) Antibody (BMS-936558) in Subjects With Relapsed or Refractory Hematologic Malignancy I Immunotherapy BMS-936558
Displaying: 1 - 8 of 8 Results
  • < Previous
  • 1
  • Next >